Biotechnology and Pharmaceutical Opptys

An Expert's View about Sales in Austria

Last updated: 31 Mar 2011

Currently more than 100 specialised companies in biotechnology and approximately 170 research institutes are active in the biotechnology sector in Austria employing more than 10 000 people.

Sector briefing Biotechnology and Pharmaceutical Opportunities in Austria Why Austria? Currently more than 100 specialised companies in biotechnology and approximately 170 research institutes are active in the biotechnology sector in Austria employing more than 10 000 people. Business volume is currently at Euro 1.9 billion. Due to public funding sources, the number of start-ups is expected to rise in the upcoming years. UK has a positive reputation in Austria and it?s membership of the European Union makes trade between Austria and the UK relatively easy. Although the official language is German, biotech clusters and multinational companies use English often as the working language. Find general information on the Austrian market conditions on UKTI's website. The Doing Business Guide for Austria gives an overview of Austria?s economy, business ?Due to public funding culture, potential opportunities and an opportunities, the number of introduction to other relevant issue start ups in the Biotechnology sector is expected to increase significantly.? UK Trade & Investment Sector briefing: Biotechnology and Pharmaceutical opportunities in Austria non profit research institute mainly funded by Opportunities Boehringer Ingelheim. Tyrol: There are various international companies Tyrol is Austria?s second most important region present in Austria such as Baxter, Boehringer for biotechnology having three universities and Ingelheim, Eli Lilly, AstraZeneca, Novartis or about 40 pharmaceutical and biotechnology Roche. Frequently Austria has been chosen not companies with R & D. Focus is on medical only for subsidiaries but also for production technology & informatics, drug development, facilities, innovation centres or CEE bioanalytics and cell therapy. headquarters. Baxter for instance, employs 3800 staff from it?s largest facility outside the Styria: USA and it?s most important research facility Having five universities Styria is important in worldwide, from Austria. education and R & D, approximately 20 companies are based there in the Joint venture and strategic partnerships in pharmaceutical and biotechnological sector research and development as well as with strong focuses in medical technology, production are widely available. pharmaceutical process engineering and health management. Compared to its gross regional Austria has put the focus on red biotechnology, product, Styria has been one of the top 20 specialised areas are as follows: regions within the EU in terms of R & D spending. ? Tumor treatments ? Orphan drugs Upper Austria: ? Pharmacogenomics Upper Austria has one university and about 40 pharmaceutical and biotechnological companies Austrian companies such as Intercell, AffiRiS with R & D. Major focus is on medical and Apeiron are already well established in the technology. market and work closely together with the world?s most important pharmaceutical Salzburg: companies. Its two universities work closely with research institutes and additional regional funding will There are a variety of research opportunities be increasing R & D even further. spread over the whole country: Vienna: If you have any questions on the opportunities The most important region for biotechnology is above, contact the UKTI contacts named in this the capital Vienna. The region has 5 report. Business opportunities aimed universities and more than 100 pharmaceutical specifically at UK companies are added daily to and biotechnology companies with R & D. The UKTI?s website. These leads are sourced by our focus is on medical biotechnology, drug staff overseas in British Embassies, High development, diagnostics and process Commissions and Consulates, across all sectors development. and in over 100 markets. The Austrian government and the city of You can be alerted to business opportunities on Vienna founded the organisation Life Sciences a regular basis by registering on the UKTI Austria Vienna Region (LISA VR) to support website. Find out more on UKTI?s business companies in the biotechnology sector and to opportunities service on the UKTI website co-ordinate research. Campus Vienna Biocenter: Campus Vienna Biocenter was founded between Viennese universities and Boehringer Ingelheim in 1992. Currently more than 900 scientists are working there. The Research Institute of Molecular Pathology (IMP), based at Campus Vienna Biocenter is a UK Trade & Investment Sector briefing: Biotechnology and Pharmaceutical opportunities in Austria Major events and activities UKTI contacts Austropharm Verena Wasenegger [http://www.austropharm.at/] Trade Officer Contact: Verena Wasenegger British Embassy Austria Email: verena.wasenegger@fco.gov.uk Tel: (43) 1 716 13 6253 Time: April 2012 Email: verena.wasenegger@fco.gov.uk www.ukti.gov.uk Karin Beck Find full details of all events in this Trade Officer country and sector on the UKTI website. British Embassy Austria New export events are added daily to the site Tel: (43) 1 716 13 2275 and you can register to be alerted to them on a Email: karin.beck@fco.gov.uk daily, weekly or monthly basis www.ukti.gov.uk UKTI?s Tradeshow Access Programme (TAP) provides grant support for eligible Small & Medium Sized Enterprises (SME's) to attend trade shows overseas. Find out more about UKTI support for attendance at overseas events UK Trade & Investment Sector briefing: Biotechnology and Pharmaceutical opportunities in Austria Next steps - How UKTI can help ? Arranging appointments British companies wishing to develop their ? Organise seminars or other events for business in the Austrian market are advised you to meet contacts and promote your to undertake as much market research and company in the Austrian market planning as possible in the UK. UKTI?s team in Austria, with its wide local knowledge and This work is available via our Overseas Market experience, can provide a range of services to Introduction Service (OMIS) a chargeable British-based companies wishing to grow their service which assists British-based companies business in global markets. wishing to enter or expand their business in overseas markets. This can include: ? Provision of market information To find out more about commissioning this ? Validated lists of agents/distributors work, or accessing other UKTI services and ? Key market players or potential specialist advice, please visit the UKTI website customers in the Austrian market to find contact details for your local UKTI ? Establishment of interest of such office. contacts in working with you Whereas every effort has been made to ensure that the information given in this document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation & Skills, and the Foreign & Commonwealth Office), accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Published 2011 by UK Trade & Investment. Crown Copyright © UK Trade & Investment Sector briefing: Biotechnology and Pharmaceutical opportunities in Austria
Posted: 29 March 2011, last updated 31 March 2011

See more from Sales in Austria

Expert Views    
Doing Business in Austria   By U.S. Commercial Service
Railway Opportunities   By UK Trade & Investment
Biotechnology and Pharmaceutical Opptys   By UK Trade & Investment
Automotive Industry Oppty in Austria   By UK Trade & Investment
EU: FEASIBILITY STUDIES AND PUBLIC PROCUREMENT   By U.S. Commercial Service Germany
Presenting the contributor